CVM News and Press, Cel-Sci Corporation From 02/15/24

CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended December 31, 2023, as well as key recent clinical and corporate developments. Clinical and Corporate Developments include: CEL-SCI identified the target head and neck cancer patient popul...

CEL-SCI Corporation (NYSE American: CVM) , a phase 3 cancer-immunotherapy company, has closed on its previously announced public offering. The offering was comprised of 3,875,000 shares of common stock, offered at $2 per share, resulting in $7.75 million in gross proceeds before deducting underwr...

CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced the closing of its previously announced public offering of 3,875,000 shares of its common stock at a public offering price of $2.00 per share,...

2024-02-12 01:21:58 ET Summary The company's focus is on its cancer pretreatment therapy, Multikine, which aims to boost the immune response before standard cancer treatments. After its long years in development, CVM is anxious for quick regulatory approval. CEL-SCI's future i...

2024-02-09 08:45:58 ET More on Cel-Sci CEL-SCI spikes as U.K. picks cancer drug, Multikine for review Seeking Alpha’s Quant Rating on Cel-Sci Read the full article on Seeking Alpha For further details see: CEL-SCI stock falls as it prices its offer...

CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced the pricing of an offering of 3,875,000 shares of its common stock at an offering price of $2.00 per share, for gross proceeds of $7.7...

Marks key achievement that is a prerequisite to filing a Biologics License Application with the FDA and other regulators for marketing approval CEL-SCI Corporation (NYSE American: CVM) today reported that its Multikine ® (Leukocyte Interleukin, Injection)* cGMP state-of-t...

CEL-SCI has cleared a significant hurdle that mandates cancer drugs in Europe comply with strict requirements for pediatric usage and clinical evidence CEL-SCI Corporation (NYSE American: CVM) today announced that the European Medicines Agency (EMA) Paediatric Committee granted CE...

2023-12-26 01:16:46 ET More on Cel-Sci CEL-SCI spikes as U.K. picks cancer drug, Multikine for review CEL-SCI climbs after ESMO data for lead asset Multikine Seeking Alpha’s Quant Rating on Cel-Sci For further details see: Cel-Sci GAAP EPS of -$0.73

2023-12-04 12:47:12 ET Gainers: Hawaiian Holdings ( HA ) +187% . EyePoint Pharmaceuticals ( EYPT ) +177% . SilverSun Technologies ( SSNT ) +176% . Alterity Therapeutics Ltd ( ATHE ) +122% . View ( VIEW ) +82% . enGene Holding...